Skip to main content
TipRanks
Go Ultimate75% OFF

National Research (NR1A) AI Stock Analysis

0 Followers
DE:NR1A

National Research

(Frankfurt:NR1A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Contract GrowthDouble-digit growth in total recurring contract value indicates durable customer demand across multiple product portfolios. Because these offerings are typically delivered through subscription and multi-period contracts, stronger bookings and retention can support more predictable revenue and provide a base for future operating leverage.
Negative Factors
Deteriorated Balance SheetHigher debt combined with negative equity materially reduces financial flexibility and leaves less room to absorb execution setbacks or fund initiatives internally. The shift from a historically conservative capital structure to elevated leverage also increases the importance of sustained cash generation and disciplined capital allocation.

National Research (NR1A) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%80%DE:NR1A+62.49%EWG+6.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 555.16M
Dividend Yield
2.42%
Average Volume (3M)
―
Price to Earnings (P/E)
86.5
Beta (1Y)
0.39
Revenue Growth
-1.84%
EPS Growth
-62.10%
Country
Germany
Employees
357
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

National Research Business Overview & Revenue Model

Company Description

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscripti...

National Research Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:18.78%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

The call was broadly positive. NRC Health reported 11% TRCV growth, solid revenue momentum despite a revenue-recognition headwind, strong pipeline and sales-activity growth, progress on the Landmark implementation, and continued product and AI innovation. The main challenges were lower year-over-year EBITDA, a decline in average deal size, temporary uncertainty following the Qualtrics and Press Ganey transaction, and unusual tax and accounting effects. Highlights significantly outweighed the lowlights.

Positive Updates

Double-Digit TRCV Growth
Total recurring contract value reached $151.9 million, increasing 11% year over year with diversified growth across the experience, market insights, and Governance Institute portfolios. Experienced TRCV grew in the mid teens compared to the prior year, driven by strong bookings activity during the first half of the year.

Negative Updates

Revenue-Recognition Headwind
A change involving the strategic replacement of a third-party vendor for certain reputation-management solutions required net revenue accounting rather than the previous gross revenue and expense treatment. This created an approximately 2-point revenue-growth headwind in the second quarter, equivalent to approximately $1.5 million on an annual basis, with a smaller headwind expected in the third and fourth quarters.

Company Guidance

The company continues to expect margin expansion in the second half of the year; for modeling purposes, third quarter revenue is expected to increase sequentially and adjusted EBITDA margin to be approximately the same as the first half of the year, with a smaller headwind in Q3 and Q4 from the accounting change, while fourth quarter adjusted EBITDA margin is expected to see upside as revenue scales and operating expenses normalize from Q3. For both Q3 and Q4, the effective tax rate is expected to be approximately 4.0%; longer term, the effective tax rate is in the high 20s, call it 28%, 29%, and cash taxes are probably more in the lower to mid-20s. The Landmark customer began contributing revenue during Q3, the next tranche of facilities will be brought on in October, deployment is expected to be complete by the end of the year, and its rounding platform is expected to kick off in the second half of 27.

National Research Risk Analysis

National Research disclosed 24 risk factors in its most recent earnings report. National Research reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

National Research Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:NR1A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DOCSDOCS80Outperform$5.54B40.8914.81%―6.48%-43.66%
WAYWAY76Outperform$5.30B39.343.41%―21.43%9.80%
PHRPHR69Neutral$760.99M71.203.01%―12.93%―
HCATHCAT54Neutral$98.24M-0.46-128.24%―-13.88%-78.38%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DHDH50Neutral$194.65M-0.89-87.69%―-6.18%10.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:NR1APHRHCATDOCSDHWAYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:NR1A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:NR1ANational Research23.409.8772.94%
PHRPhreesia12.26-7.79-38.85%
HCATHealth Catalyst1.29-1.07-45.34%
DOCSDoximity, Inc.30.67-19.75-39.17%
DHDefinitive Healthcare Corp. Class A1.34-1.42-51.45%
WAYWaystar Holding Corp.27.54-8.20-22.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.